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South Africa is a middle-income country with the world’s largest HIV patient
cohort and a growing burden of communicable and non-communicable
diseases -- a prime location for pharmaceutical companies looking to expand
their markets. Yet, 20 years after the country’s first democratic elections,
poor health indicators and an over-burdened public health system belie
persistently stark levels of socioeconomic inequality. As the South African
government revises national intellectual property (IP) policies, the pharma-
ceutical industry and global access to medicines movement are watching,
aware of ramifications South Africa’s actions will have on patent laws and
the availability of generic medicines in other middle-income countries and
across Africa. South Africa’s draft IP policy is meeting fierce resistance from
industry, although proposed reforms are compliant with the Agreement on
trade related aspects of intellectual property (TRIPS) and in line with on-going
policies and actions of both developing and developed countries. Could the
establishment of a patent examination system and new patentability criteria
rein in evergreening and lead to lower medicine prices? What will be the
potential impact of reform on medical innovation? And why is it both neces-
sary and urgent that the South African government seek a fairer balance
between private and public interests?
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1. Introduction: what is at stake in South Africa’s intellectual
property debate?
In January 2014, South Africa’s Mail & Guardian ran a front-page headline quote
from the Minister of Health, Aaron Motsoaledi: ‘This is genocide’ [1]. The accused
was the Innovative Pharmaceutical Association of South Africa (IPASA), a trade
association of 26 multinational pharmaceutical companies. A leaked strategy docu-
ment drafted by US lobbying firm Public Affairs Engagement (PAE), accompanied
by an email from Merck Sharp & Dohme’s Michael Azrak to other companies’
IPASA Board representatives, outlined a plan to covertly delay the South African
government’s finalization of a new national intellectual property (IP) policy [2].
With financial backing from the Pharmaceutical Research and Manufacturers of
America (PhRMA), IPASA budgeted US$600,000 to utilize South African organi-
zations and politicians as a front for promoting their policy objectives. Motsoaledi’s
reference to a ‘satanic plot’ may suggest hyperbole, but his concerns should not be
dismissed lightly.
A battle is underway in South Africa -- terrain the PAE strategy referred to as
‘ground zero’ for companies aiming to protect pharmaceutical IP rights in MICs
and growing African markets. South Africa is a country where over two million
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patients have initiated antiretroviral therapy, over 14,000
drug-resistant tuberculosis (DR-TB) infections were recorded
in 2012, and there is a growing burden of non-communicable
diseases [3-5]. Yet, half the population lives on < $3/day, and
public health spending -- a staggering 11% of the annual gov-
ernment budget -- supports over 80% of the population’s
health needs, although expenditures per capita in the private
system are up to ten times higher [6].
The point of contention is the Draft National Policy on
Intellectual Property, 2013 (DNPIP), released by the Depart-
ment of Trade and Industry (DTI) for public comment in
September 2013 [7]. The DNPIP’s most significant reforms
are those addressing the effects of patent laws on public health,
and seeking to keep medicine prices in check by facilitating the
timely use of flexibilities outlined in the Agreement on Trade
Related Aspects of Intellectual Property Rights (TRIPS).
Many reforms are vocally supported by the ‘Fix the Patent
Laws’ campaign -- a civil society coalition led by the Treatment
Action Campaign, Section27 and Doctors Without Borders
(MSF) [8]. The multinational pharmaceutical industry, by con-
trast, is attempting to preserve the existing climate in South
Africa, which is one of the most lenient in the world in grant-
ing patents and has limited effectiveness employing TRIPS
flexibilities to access more affordable generic medicines.
Recent public backlash against ‘Pharmagate’ evokes de´ja` vu
from 1998. Then, 39 multinational pharmaceutical companies
tookNelsonMandela’s government to court, questioning South
Africa’s right to import cheaper medicines from other jurisdic-
tions. The laws in question were fully TRIPS-compliant -- in
fact, a product of technical assistance from the World Intellec-
tual Property Organization [9]. In light of this, and facing a
public relations disaster, the pharmaceutical companies were
eventually forced to drop the case and accept that they could
not bully the country into creating pro-industry laws that
ignored public health considerations. The case eventually galva-
nized aWorld Trade Organization agreement: the Doha Decla-
ration on TRIPS and Public Health, which stated unequivocally
that ‘the TRIPS Agreement does not and should not prevent
members from taking measures to protect public health’.
Reforms proposed in the DNPIP are a continuation of
previous government efforts to meet the state’s obligations
under Section 27 of the South African Constitution. ‘The state
must take reasonable legislative and other measures’ to progres-
sively realize the right of everyone in South Africa to have access
to healthcare services, which includes access to medicines [10].
With IP policies that are outdated, unimplemented or incoher-
ent due to ad hoc legislative changes since the end of apartheid,
several substantial tasks lie ahead. Most notably, the DTI
intends to establish a substantive patent examination system
and supplementary measures to curb the practice of evergreen-
ing, and positively influence competition, affordability and
innovation in the pharmaceutical market [11].
This article focuses on why patent evergreening is problem-
atic in blocking access to affordable medicines in South
Africa, and which proposed reforms, once implemented,
could stop frivolous granting of pharmaceutical patents and
enhance cost savings. The article also considers the impact
stopping evergreening will (or will not) have on innovation
for developing medicines needed in South Africa, and how
South Africa’s government could continue to defy industry
pressures by prioritizing the finalization and implementation
of a national IP policy.
2. Pharmaceutical patent evergreening:
limiting competition in South Africa
South Africa’s patent office, which is housed within the
Companies and Intellectual Property Commission (CIPC),
does not substantively examine patent applications to ensure
national criteria for granting a patent are met. Instead, CIPC
registers any patent when the proper paperwork is filed and
fees paid [12]. Pharmaceutical companies take advantage of this
lack of scrutiny by filing new patent applications on minor
modifications of existing products (e.g., on a combination of
several drugs in one pill, a new use for a drug, a reformulation),
typically several years after the initial patent was filed. This prac-
tice, known as ‘evergreening’, allows originator companies to
continue blocking generic competitors from entering the
market when the initial patent expires and maintain the ability
to charge high prices. Although the practice of evergreening is
not exclusive to South Africa, the problem there is particularly
acute, due to the absence of an examination system. Because
no complete application is rejected, South Africa grants an
extraordinary number of patents on pharmaceuticals -- 2442
patents in 2008 alone. By contrast, Brazil -- which does conduct
substantive examination -- granted only 273 patents on pharma-
ceuticals between 2003 and 2008 [13]. South African patent
practices are not only unusual for an MIC -- in a sampling of
identical pharmaceutical patent applications filed in various
jurisdictions between 2000 and 2002; the US Patent and
Trademark Office and European Patent Office both rejected
~ 40% of the applications granted by South Africa [14].
Proliferation of secondary patents creates a culture of
uncertainty and leads to fear of patent infringement, thereby
discouraging generic drug manufacturers from marketing
more affordable medicines. For example, the original South
African patent held by Novartis on cancer treatment imatinib
expired in April 2013; however, a new-use patent on imatinib
runs until 2022 [15,16]. Only one generic drug company, Cipla,
has entered the market to date, after reaching an unpublicized
agreement with Novartis. Other would-be competitors will
also contend with Novartis until the secondary patent expires.
To realize prices found in India -- where, according to MSF,
over ten competitors sell imatinib, and Cipla markets the drug
at a price 91% lower than in South Africa -- reform that pro-
motes greater competition with multiple generic drug manufac-
turers on the market is necessary [17]. As a solution, in the
DNPIP, the DTI proposes a multi-pronged approach to
enhance both the standard for innovation to which a patent
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application is upheld, and the scrutiny to which the application
is subjected to ensure it meets national criteria.
3. Can IP reforms improve access to more
affordable medicines?
The DNPIP recommends excluding from patentability
‘diagnostic, therapeutic and surgical methods…, including
new uses of known products’, noting this is compliant with
TRIPS. South Africa could also consider other countries’ recent
interpretations of the definitions of ‘novelty’ and ‘inventive
step’. For example, the Indian Patents Act’s Section 3(d) specif-
ically acts to limit patent evergreening by excluding from
patentability modifications of known substances (such as
pharmaceuticals), unless the modification results in ‘enhanced
efficacy’ [18]. New patent examination guidelines issued in
Argentina contain more comprehensive exclusion criteria than
India and no inclusion of an ‘enhanced efficacy’ provision [19].
Under this interpretation, if a pharmaceutical compound is
part of the state of the art, the public health considerations of
accessing more affordable generics outweigh commercial inter-
ests of the originator company. In the 5 months prior to the
guidelines going into force, Argentina granted 53 pharmaceuti-
cal patents; in the 7 months following, it granted only two [20].
By enacting similar criteria, South Africa could easily reduce the
number of pharmaceutical patents granted to a fraction of the
current level.
New patentability criteria will have limited impact on ever-
greening, however, if the current patent registration system
remains intact. The DNPIP identifies several ways to improve
adherence to patentability criteria and the subsequent quality
of South African patents granted. First, the DNPIP proposes
the establishment of a patent examination system. This would
bring South Africa in compliance with Section 34 of the Pat-
ents Act of 1978, which mandates substantive examination.
To date, resources have not been allocated to implement
such a system. Pre- and post-grant patent opposition would
also be established to serve as an essential procedural safe-
guarding for the formal examination system. Unmentioned
by the DNPIP are complementary reforms required to make
proposed systems a reality: a plan must be established to
recruit and train examiners; a viable fee structure for patent
applications and maintenance will be necessary to sustain
the increased human resources required by an examination
system; and transparency of the CIPC should be enhanced
through improved IT systems and online search capabilities,
to facilitate examination and opposition procedures.
4. Ending evergreening in South Africa: only
one step towards promoting needed medical
innovation
Proposed South African reforms are discussed by the Pharma-
gate PAE strategy with a Cold War-era ‘domino effect’
mentality -- another nation from the Brazil-Russia-India-
China-South Africa (BRICS) group is falling into the morass
of public health-oriented IP policy, with more countries to
follow suit. Sub-Saharan Africa, however, makes up only
1.2% of global pharmaceutical revenues [21]. Curbing evergre-
ening in South Africa -- even as the largest emerging pharma-
ceutical market in the region -- is unlikely to put a serious dent
in the US$600 billion in global annual revenues of the
branded medicines market, or further reduce the already-low
16.4% of revenues PhRMA members claimed they spent on
medical research and development (R&D) in 2012. More
countries could weary of providing financial rewards for
follow-on pharmaceutical modifications with limited to no
therapeutic impact. If so, widespread rejection of frivolous
patents and higher expectations for innovation could result
in a refreshing new reality: rather than pharmaceutical manu-
facturers investing significant time and energy into develop-
ment of me-too drugs, or tweaking existing compounds to
extend the lifetime of a drug’s profitability, more resources
might instead be devoted toward R&D for a greater number
of new drugs and breakthrough forms of treatment.
Limiting evergreening would facilitate the development of
competitive markets when demand for medicines spans both
wealthy and poorer economic classes. A patent examination
system, however, is unlikely to either hinder or help R&D
investment for treatments needed almost exclusively by poorer
South Africans. Current innovation models are dependent on
products’ commercial viability to create a return on invest-
ment in R&D, and have historically neglected the medical
needs of low-income populations. Different incentives are
needed -- referred to as ‘alternatives to IP’ in the DNPIP --
to develop treatments the pharmaceutical industry has aban-
doned or ignored, and ‘de-link’ the cost of R&D from the
private sector’s modus operandi of charging high prices to
re-coup investment. Early-stage financing for neglected areas
of research, push funding that can finance pre-clinical R&D
or clinical trials, milestone and end-stage prizes that are
conditional on the open licensing of IP, and market shaping
that encourages competition, could all contribute to de-
linking [22]. New IP policies in South Africa should ensure
medical innovation financed with public funds is coupled
with government actions that promote the principles of
de-linkage and affordability, so that needed therapies do not
fall by the wayside due to lack of commercial interest.
5. Expert opinion
The government of South Africa has both national obligations
and rights under international agreements to develop policies
to protect access to lifesaving medicines, and to promote the
development and affordability of needed new treatments.
National political will is often the only way to counter the
ostentatious Pharmagate assumption that industry cash flows
can block a country’s adoption and implementation of TRIPS
flexibilities. The public health protections enshrined in the
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Doha Declaration must take precedent over opinions founded
in corporate interest, such as Bayer CEO, Marijn Dekkers’
recent statements that his company’s cancer treatment was
not developed for the Indian market, but ‘for Western
patients who could afford [it]’ [23].
For the DTI to better ensure affordability of medicines to
rich and poor alike in South Africa, it must put a stop to
evergreening. Expanded justifications for establishing a patent
examination system, new patentability criteria, patent opposi-
tion and other reforms should be incorporated into a finalized
IP policy. The DTI promises policy finalization is underway,
led by an inter-departmental government task force [24]. This
task force should proactively detail how it envisions the estab-
lishment of systems already mandated by law -- particularly,
a patent examination system.
Building capacity of patent examiners will require a
sustained, multi-year effort and adequate financial resources,
but South Africa does not need to create the system from
scratch, nor wait years to start examining pharmaceutical
patents. It can draw upon the recent experiences of, and reach
out for technical assistance from BRICS partners Brazil and
India, which have implemented reforms to limit evergreening
in the recent past. To address potential capacity constraints,
South Africa could prioritize training of patent examiners in
fields relevant to the public interest, such as pharmaceuticals.
In order to maintain compliance with Article 27.1 of TRIPS,
South Africa could also detail a schedule for the eventual
examination of all patent categories.
Patent thickets have already sprung up in South Africa
around promising new treatments for drug-resistant forms
of HIV and TB. These patents interfere with access and
with development of appropriate regimens and fixed dose
combinations. If South Africa is to have the legal tools avail-
able to challenge patents granted too easily and to reject
patent applications that are meritless, IP reform cannot be
delayed.
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